An interesting turn of events for GSK and the BCMA niche

Was the ODAC hearing a win or loss in the GSK vs FDA battle for the first BCMA approval?

July 14, 2020

Alternative cell therapy approaches to tackling cancer

How can we go about improving cell therapy approaches?

March 26, 2020

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020

Novel Targets and Agents – Part 2

In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…

March 20, 2020

How to tackle immune suppression in multiple myeloma

Tackling immune suppression in hematologic malignancies may improve outcomes with existing regimens

March 18, 2020

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020

Lining up multiple approaches in AML

Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.

January 23, 2020

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020

Lining up new developments in the treatment of GVHD

Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.

January 13, 2020

The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020

Novel agents and targets – Part 1

Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies

December 19, 2019

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019

Friday Scientific Workshops are the Perfect Warm-Up act to ASH19

Science Friday at ASH19 with a look at various lymphoma and myeloma developments

December 7, 2019

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019

9 up and coming non-T cell based immunotherapy approaches

Non-T cell based immunotherapies that could be promising in hematologic malignancies

November 21, 2019

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019

New developments in targeting the B cell receptor pathway

It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!

November 7, 2019